Continued Improvement in Myocardial T2* Over Two Years of Deferasirox Therapy in ?-Thalassemia Major Patients with Cardiac Iron Overload

Citation:
Pennell, D. J., J. B. Porter, M. D. Cappellini, L. L. Chan, A. El-Beshlawy, Y. Aydinok, H. Ibrahim, C. - K. Li, V. Viprakasit, M. S. Elalfy, et al., "Continued Improvement in Myocardial T2* Over Two Years of Deferasirox Therapy in ?-Thalassemia Major Patients with Cardiac Iron Overload", Haematologica, 2011.

Abstract:

Background: The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with ?-thalassemia major in the cardiac sub-study of the EPIC trial.

Notes:

n/a

PreviewAttachmentSize
cu_pdf.pdf375.47 KB
Tourism